Extracellular matrix proteins matrix metallopeptidase 9 (MMP9) and soluble intercellular adhesion molecule 1 (sICAM-1) and correlations with clinical staging in euthymic bipolar disorder

Bipolar Disorders

Volumn 18, Issue 2, 2016, Pages 155-163

  Reininghaus, Eva Z ^a   Lackner, Nina ^a   Birner, Armin ^a   Bengesser, Susanne ^a   Fellendorf, Frederike T ^a   Platzer, Martina ^a   Rieger, Alexandra ^a,b   Queissner, Robert ^a   Kainzbauer, Nora ^a   Reininghaus, Bernd ^a   Mcintyre, Roger S ^c,d   Mangge, Harald ^a   Zelzer, Sieglinde ^a   Fuchs, Dietmar ^e   Dejonge, Silvia ^f   Müller, Norbert ^f  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Bipolar disorder; Cardiovascular disease; Extracellular matrix proteins; Intercellular adhesion molecule; Matrix metallopeptidase 9; Obesity

Indexed keywords

GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; SCLEROPROTEIN;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STAGING; BLOOD; CARDIOVASCULAR DISEASE; COGNITION; COMPLICATION; DISEASE COURSE; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICS;

ADULT; BIOMARKERS; BIPOLAR DISORDER; CARDIOVASCULAR DISEASES; COGNITION; DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC;

EID: 84961627378     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12380     Document Type: Article

References (51)

1. Kapczinski F, Dal-Pizzol F, Teixeira AL et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2011; 45: 156-161.
2. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-817.
3. Soczynska JK, Kennedy SH, Woldeyohannes HO et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med 2011; 13: 93-116.
4. Blann AD, Lip GY. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul Fibrinolysis 1998; 9: 297-306.
5. Hillis GS, Flapan AD. Cell adhesion molecules in cardiovascular disease: a clinical perspective. Heart 1998; 79: 429-431.
6. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
7. Blankenberg S, Rupprecht HJ, Poirier O et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-1585.
8. Horne BD, Camp NJ, Carlquist JF et al. Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am Heart J 2007; 154: 751-758.
9. Garvin P, Nilsson L, Carstensen J et al. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS ONE 2008; 3: e1774.
10. Zhang B, Ye S, Herrmann SM et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788-1794.
11. Dhingra R, Pencina MJ, Schrader P et al. Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community. Circulation 2009; 119: 1101-1107.
12. Rothlein R, Mainolfi EA, Czajkowski M et al. A form of circulating ICAM-1 in human serum. J Immunol 1991; 147: 3788-3793.
13. Krenn V, Schedel J, Doring A et al. Endothelial cells are the major source of sICAM-1 in rheumatoid synovial tissue. Rheumatol Int 1997; 17: 17-27.
14. Ben-Shachar D, Livne E, Spanier I et al. Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake. J Neurochem 1994; 62: 1112-1118.
15. Rieckmann P, Nunke K, Burchhardt M et al. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. J Neuroimmunol 1993; 47: 133-140.
16. Fiore E, Fusco C, Romero P et al. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 2002; 21: 5213-5223.
17. Onore CE, Nordahl CW, Young GS et al. Levels of soluble platelet endothelial cell adhesion molecule-1 and P-selectin are decreased in children with autism spectrum disorder. Biol Psychiatry 2012; 72: 1020-1025.
18. Reininghaus EZ, Lackner N, Fellendorf FT et al. Weight cycling in bipolar disorder. J Affect Disord 2015; 171: 33-38.
19. Bengesser SA, Lackner N, Birner A et al. Peripheral markers of oxidative stress and antioxidative defense in euthymia of bipolar disorder-Gender and obesity effects. J Affect Disord 2014; 172C: 367-374.
20. Lackner N, Mangge H, Reininghaus EZ et al. Body fat distribution and associations with metabolic and clinical characteristics in bipolar individuals. Eur Arch Psychiatry Clin Neurosci 2015; 265: 313-319.
21. Reininghaus EZ, McIntyre RS, Reininghaus B et al. Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. Bipolar Disord 2014; 16: 432-440.
22. Kapczinski F, Dias VV, Kauer-Sant'Anna M et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother 2009; 9: 957-966.
23. Niemann H, Sturm W, Thöne-Otto A et al. California Verbal Learning Test, 2008.
24. Reitan RM. Trail Making Test: manual for administration and scoring. Tucson, AZ: Reitan Neuropsychology Laboratory, 1992.
25. Bäumler G, Stroop JR. Farbe-Wort-Interferenztest nach JR Stroop (FWIT). Verlag für Psychologie: Hogrefe, 1985.
26. Brickenkamp R. Test d2: Aufmerksamkeits-Belastungs-Test; Manual. Hogrefe: Verlag für Psychologie. Hogrefe, Verlag für Psychologie, 2002.
27. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-512.
28. Schwarz MJ, Riedel M, Ackenheil M et al. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol Psychiatry 2000; 47: 29-33.
29. Schaefer M, Horn M, Schmidt F et al. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha. Brain Behav Immun 2004; 18: 555-562.
30. Lee KS, Jin SM, Kim HJ et al. Matrix metalloproteinase inhibitor regulates inflammatory cell migration by reducing ICAM-1 and VCAM-1 expression in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol 2003; 111: 1278-1284.
31. Baraczka K, Nekam K, Pozsonyi T et al. Concentration of soluble adhesion molecules (sVCAM-1, sICAM-1 and sL-selectin) in the cerebrospinal fluid and serum of patients with multiple sclerosis and systemic lupus erythematosus with central nervous involvement. Neuro Immuno Modulation 2001; 9: 49-54.
32. Engelhardt B, Conley FK, Butcher EC. Cell adhesion molecules on vessels during inflammation in the mouse central nervous system. J Neuroimmunol 1994; 51: 199-208.
33. Risau W, Esser S, Engelhardt B. Differentiation of blood-brain barrier endothelial cells. Pathol Biol 1998; 46: 171-175.
34. Kaczmarek L, Lapinska-Dzwonek J, Szymczak S. Matrix metalloproteinases in the adult brain physiology: a link between c-Fos, AP-1 and remodeling of neuronal connections? EMBO J 2002; 21: 6643-6648.
35. Bonaccorso S, Puzella A, Marino V et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001; 105: 45-55.
36. Licinio J, Kling MA, Hauser P. Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol 1998; 25: 30-38.
37. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000; 157: 683-694.
38. Taylor JL, Grossberg SE. The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol 1998; 25: 23-29.
39. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001; 2 (7): 502-511.
40. Brusés JL. Cadherin-mediated adhesion at the interneuronal synapse. Curr Opin Cell Biol 2000; 12: 593-597.
41. Ganguly K, Rejmak E, Mikosz M, Nikolaev E, Knapska E, Kaczmarek L. Matrix Metalloproteinase (MMP)-9 transcription in mouse brain induced by fear learning. J Biol Chem 2013; 288: 20978-20991.
42. Szklarczyk A, Lapinska J, Rylski M, McKay RD, Kaczmarek L. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J Neurosci 2002; 22: 920-930.
43. Rosell A, Ortega-Aznar A, Alvarez-Sabín J et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006; 37: 1399-1406.
44. Rybakowski JK. Matrix Metalloproteinase-9 (MMP9)-A mediating enzyme in cardiovascular disease, cancer, and neuropsychiatric disorders. Cardiovasc Psychiatry Neurol 2009; 2009: 904836.
45. Rybakowski JK, Skibinska M, Leszczynska-Rodziewicz A et al. Matrix metalloproteinase-9 gene and bipolar mood disorder. Neuromolecular Med 2009; 11: 128-132.
46. Rosenblat JD, McIntyre RS. Are medical comorbid conditions of bipolar disorder due to immune dysfunction? Acta Psychiatr Scand 2015; 132: 180-191.
47. Welsh P, Whincup PH, Papacosta O et al. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM 2008; 101: 785-791.
48. Hunt BJ, Jurd KM. Endothelial cell activation. A central pathophysiological process. BMJ 1998; 316: 1328-1329.
49. Cotran RS, Mayadas-Norton T. Endothelial adhesion molecules in health and disease. Pathol Biol 1998; 46: 164-170.
50. Libby P, Aikawa M, Kinlay S et al. Lipid lowering improves endothelial functions. Int J Cardiol 2000; 74 (Suppl. 1): S3-S10.
51. Glowinska B, Urban M, Peczynska J et al. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes. Metabolism 2005; 54: 1020-1026.